AstraZeneca Plc (AZN)

39.59
0.10 0.25
NYSE : Health Technology
Prev Close 39.49
Open 39.16
Day Low/High 39.03 / 39.76
52 Wk Low/High 31.99 / 40.16
Volume 4.60M
Avg Volume 4.03M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 98.05B
EPS 1.20
P/E Ratio 17.58
Div & Yield 1.37 (3.52%)
Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Better-than-expected earnings from a number of key Dow components sweep markets higher.

(Photo: Business Wire)

(Photo: Business Wire)

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BYDUREON ® BCise™ (exenatide extended-release) injectable suspension, a new formulation of BYDUREON ® (exenatide...

AstraZeneca Announces New Data Showing US Preterm Infants At Significantly Greater Risk Of RSV Hospitalizations Following 2014 Guidance Change

AstraZeneca Announces New Data Showing US Preterm Infants At Significantly Greater Risk Of RSV Hospitalizations Following 2014 Guidance Change

AstraZeneca today announced new results of a study that investigated respiratory syncytial virus (RSV) hospitalization risk and costs during the 2014-2016 RSV seasons compared to the 2012-2014 RSV seasons.

US FDA Accepts Supplemental Biologics License Application For IMFINZI® (durvalumab) In Locally Advanced, Unresectable Non-Small Cell Lung Cancer

US FDA Accepts Supplemental Biologics License Application For IMFINZI® (durvalumab) In Locally Advanced, Unresectable Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for IMFINZI ® ...

Flexion's Latest FDA Approval Reignites Takeover Chatter

Flexion's Latest FDA Approval Reignites Takeover Chatter

The Burlington, Mass.-based pharmaceutical firm on Oct. 6 secured approval from the Food and Drug Administration for its osteoarthritis knee pain treatment Zilretta, a non-opioid medicine.

TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation By US FDA For The 1st-Line Treatment Of Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation By US FDA For The 1st-Line Treatment Of Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for TAGRISSO ® (osimertinib) for the 1st-line treatment of patients with metastatic...

3 Small Biotech Stocks Insiders Are Buying

3 Small Biotech Stocks Insiders Are Buying

Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.

Markets Move Higher; Inversion Rules Put Pfizer-Allergan Back In Focus -- ICYMI

Markets Move Higher; Inversion Rules Put Pfizer-Allergan Back In Focus -- ICYMI

Here's what you need to know now for Monday, Oct. 2.

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Newly public companies such as Roku, NuCana and Restoration Robotics could bring a jolt to your portfolio. But remember all IPOs aren't created equally.

CEOs Are Dropping Like Flies

CEOs Are Dropping Like Flies

So far in 2017, we have had to say farewell to many CEOs, including these.

Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile And Fewer CV Events In Patients With Type-2 Diabetes At Wide Range Of CV Risk

Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile And Fewer CV Events In Patients With Type-2 Diabetes At Wide Range Of CV Risk

AstraZeneca today announced full results from the EXSCEL ( EX enatide S tudy of C ardiovascular E vent L owering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in...

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

Wall Street starts the week with a rally.

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

The Dow is up more than 250 points.

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

The world's biggest generic drug maker Monday named Kare Schultz as president and CEO, ending months of speculation about who would replace former head Erez Vigodman, who left the company in February for undisclosed reasons.

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Wall Street moves higher.

AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results

AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results

AstraZencea shares topped London's FTSE 100 Monday after better-than-expected results in a key lung cancer treatment trial.

AstraZeneca Presents Superior Progression-Free Survival For IMFINZI® (durvalumab) In The Pacific Trial Of Patients With Locally-Advanced Unresectable Lung Cancer At ESMO 2017 Congress

AstraZeneca Presents Superior Progression-Free Survival For IMFINZI® (durvalumab) In The Pacific Trial Of Patients With Locally-Advanced Unresectable Lung Cancer At ESMO 2017 Congress

AstraZeneca and MedImmune, its global biologics research and development arm, today announced the full progression-free survival (PFS) data from a planned interim analysis of the investigational Phase III PACIFIC trial.

AstraZeneca's TAGRISSO® (osimertinib) Shows Potential As A New Standard Of Care In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer At ESMO 2017 Congress

AstraZeneca's TAGRISSO® (osimertinib) Shows Potential As A New Standard Of Care In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer At ESMO 2017 Congress

AstraZeneca today announced the full results of the Phase III FLAURA trial, which support TAGRISSO ®'s (osimertinib) clear potential as a new standard of care (SoC) in the 1st-line treatment of adult patients with...

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.

FASLODEX® (fulvestrant) Receives US FDA Approval As Monotherapy For Expanded Use In HR+, HER2- Advanced Breast Cancer

FASLODEX® (fulvestrant) Receives US FDA Approval As Monotherapy For Expanded Use In HR+, HER2- Advanced Breast Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved FASLODEX ® (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal...

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

LYNPARZA® (olaparib) Receives Additional FDA Approval In The US For Ovarian Cancer

LYNPARZA® (olaparib) Receives Additional FDA Approval In The US For Ovarian Cancer

AstraZeneca and Merck & Co., Inc.

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

The drug would be the first such treatment in Europe.

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of the hottest biotech stocks of the last month is selling off.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Acalabrutinib Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Mantle Cell Lymphoma

Acalabrutinib Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Mantle Cell Lymphoma

AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for...

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

A glimpse of what to expect during Tuesday's pre-market.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

TheStreet Quant Rating: B (Buy)